A note of caution regarding bortezomib, lenalidomide and dexamethasone (VRD) treatment in systemic AL Amyloidosis
With PBS reimbursement from 1 June 2020 of the bortezomib, lenalidomide and dexamethasone (VRD) triplet as frontline treatment for newly diagnosed myeloma, the Australian Amyloidosis Network would like to highlight the reported international experience of VRD in systemic AL amyloidosis, and provide a note of caution.
Good Clinical Trials Collaborative Global Survey
Calling all researchers whose trial has been affected by COVID-19, pls consider spending 10mins to complete this GLOBAL SURVEY https://wellcome.ac.uk/what-we-do/our-work/good-clinical-trials-collaborative to capture overall impact & innovate future research practice #clinicaltrials
Do you have Multiple Myeloma?
Given the abundance of research supporting that sexual concerns are highly prevalent in cancer survivors, it follows that this could also be true for patients with multiple myeloma specifically. The study is run by University of Calgary and Tom Baker Cancer Centre in Canada.